MacroGenics drops after FDA partial clinical hold on lead program
Source: SeekingAlpha
2026-02-24 06:49:15 ET
More on MacroGenics
- Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication
- Seeking Alpha’s Quant Rating on MacroGenics
- Historical earnings data for MacroGenics
- Financial information for MacroGenics
Read the full article on Seeking Alpha
For further details see:
MacroGenics drops after FDA partial clinical hold on lead program
MacroGenics Inc.
NASDAQ: MGNX
MGNX Trading
8.35% G/L:
$2.14 Last:
461,233 Volume:
$2.07 Open:
MGNX Latest News
February 23, 2026 06:14:00 pm
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
November 25, 2025 04:05:00 pm
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
November 12, 2025 04:01:00 pm
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
MGNX Stock Data
$110,069,846
55,034,923
1.49%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
